{"prompt": "['Investigational Product (KPT-330)', 'Karyopharm Therapeutics Inc.', 'Clinical Study Protocol: KCP-330-023', '17 August 2018', '12-lead electrocardiogram (ECG) results, ophthalmic examination results, and clinical', 'laboratory results', 'Secondary HR-QoL Endpoint', 'Patient-reported peripheral neuropathy, as measured by the EORTC QLQ-CIPN20 instrument', 'Study Location:', 'Approximately 120 global investigative sites are planned.', 'Number of Patients (planned):', 'Approximately 364 patients will be randomized. The number of patients enrolled may be adjusted based', 'on the results of the interim analysis (IA) for sample size re-estimation (first IA).', 'Study Population: This study will enroll patients >18 years of age with RRMM who have received 1 to', '3 prior anti-MM regimens and who meet all of the inclusion criteria and none of the exclusion criteria.', 'Randomization:', 'Patients (~364) will be randomized to 1 of 2 treatment arms (SVd or Vd) in a 1:1 allocation, as follows:', 'SVd Arm (~182): selinexor + bortezomib (QW) + dexamethasone', 'Vd Arm (~182): bortezomib (Cycles 1-8 [twice weekly], Cycles >9 [QW]) + dexamethasone', 'Randomization will be stratified based on the following stratification factors and will maintain the 1:1', 'allocation between treatment arms (SVd, Vd) within each of the stratification categories:', 'Prior PI therapies (Yes or No)', 'Number of prior anti-MM regimens (1 versus >1)', 'Revised International Staging System (R-ISS) stage based on screening results (R-ISS Stage III', 'versus R-ISS Stage I or II) (Palumbo 2015).', 'It is planned to randomize patients within individual countries in a 1:1 allocation to SVd:Vd.', 'Test Product, Dose, and Mode of Administration:', 'SVd Arm:', 'Selinexor will be given as a fixed oral 100 mg dose (five 20 mg tablets) on Days 1, 8, 15, 22,', 'and 29 of each 35-day cycle.', 'Bortezomib will be given at a dose of 1.3 mg/m\u00b2 SC on Days 1, 8, 15, and 22 of each 35-day', 'cycle.', 'Dexamethasone will be given as an oral 20 mg dose on Days 1,2,8,9,15,16,22,23,29, and', '30 of each 35-day cycle.', 'Vd Arm:', 'Bortezomib will be given at a dose of 1.3 mg/m\u00b2 SC on Days 1, 4,8, and 11 of each 21-day', 'cycle for the first 8 cycles. For Cycles 9, bortezomib will be given at a dose of 1.3 mg/m\u00b2 SC', 'on Days 1, 8, 15, and 22 of each 35-day cycle.', 'Dexamethasone will be given as an oral 20 mg dose on Days 1, 2, 4, 5, 8, 9, 11, and 12 of each', '21-day cycle for the first 8 cycles. For Cycles 9, dexamethasone will be given as an oral 20 mg', 'dose on Days 1, 2, 8, 9, 15, 16, 22, 23, 29, and 30 of each 35-day cycle.', 'Confidential', 'Page 20', 'Version 4.0']['Investigational Product (KPT-330)', 'Karyopharm Therapeutics Inc.', 'Clinical Study Protocol: KCP-330-023', '17 August 2018', 'After IRC-confirmed PD, patients in the Vd Arm may cross over to SVdX (returning to Cycle 1) if they', 'are able to tolerate continued bortezomib or to SdX if they have significant tolerability issues with', 'bortezomib.', 'Selinexor Dose Escalation', 'A selinexor dose escalation may be considered for patients being treated with a selinexor-containing', 'regimen (ie, SVd Arm, SVdX treatment, or SdX treatment) who meet the following 3 criteria: 1) do not', 'achieve at least a PR within the first 2 cycles, 2) are tolerating SVd well at dose level 0, and 3) do not', 'have any AEs related to study treatment Grade >2 (National Cancer Institute [NCI] Common', 'Terminology Criteria for Adverse Events [CTCAE] version 4.03) at the time of dose escalation. For', 'Cycles >3, selinexor may be increased to a fixed oral 60 mg dose twice weekly during Weeks 1 through', '5. For patients who dose escalate, selinexor will be given as a fixed oral 60 mg dose on Days 1, 3, 8, 10,', '15, 17, 22, 24, 29, and 31 of each 35-day cycle. Dexamethasone (20 mg) will be given on the same days', 'as selinexor.', 'Duration of Treatment and Follow-up:', 'Study treatment (SVd, Vd, SVdX, or SdX) may continue until PD is confirmed by the IRC, Investigator', 'or patient decision to discontinue study treatment, pregnancy, unacceptable AEs or toxicity that cannot', 'be managed by supportive care, withdrawal of consent, death, or Sponsor decision to terminate the', 'study. After discontinuation of SVd, Vd, SVdX, or SdX patients will be followed for survival every', '3 months until the end of study (ie, when the last patient treated in the study has been followed for up to', '5 years after their last dose of SVd/Vd/SVdX/SdX treatment).', 'Statistical Methods:', 'Sample Size Calculation and Statistical Power:', 'Confidential', 'Page 21', 'Version 4.0']\n\n###\n\n", "completion": "END"}